Literature DB >> 15306602

Biologics in inflammatory bowel disease: how much progress have we made?

W J Sandborn1, W A Faubion.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15306602      PMCID： PMC1774209          DOI： 10.1136/gut.2003.025452

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  56 in total

Review 1.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  A preliminary study of growth hormone therapy for Crohn's disease.

Authors:  A E Slonim; L Bulone; M B Damore; T Goldberg; M A Wingertzahn; M J McKinley
Journal:  N Engl J Med       Date:  2000-06-01       Impact factor: 91.245

3.  Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.

Authors:  S Schreiber; S Nikolaus; H Malchow; W Kruis; H Lochs; A Raedler; E G Hahn; T Krummenerl; G Steinmann
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

4.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease.

Authors:  J F Colombel; P Rutgeerts; H Malchow; M Jacyna; O H Nielsen; J Rask-Madsen; S Van Deventer; A Ferguson; P Desreumaux; A Forbes; K Geboes; L Melani; M Cohard
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

5.  An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

Authors:  W J Sandborn; B G Feagan; S B Hanauer; D H Present; L R Sutherland; M A Kamm; D C Wolf; J P Baker; C Hawkey; A Archambault; C N Bernstein; C Novak; P K Heath; S R Targan
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

6.  Beta2 integrin/ICAM expression in Crohn's disease.

Authors:  C N Bernstein; M Sargent; W M Gallatin
Journal:  Clin Immunol Immunopathol       Date:  1998-02

7.  A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

Authors:  F H Gordon; C W Lai; M I Hamilton; M C Allison; E D Srivastava; M G Fouweather; S Donoghue; C Greenlees; J Subhani; P L Amlot; R E Pounder
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

8.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.

Authors:  S Schreiber; R N Fedorak; O H Nielsen; G Wild; C N Williams; S Nikolaus; M Jacyna; B A Lashner; A Gangl; P Rutgeerts; K Isaacs; S J van Deventer; J C Koningsberger; M Cohard; A LeBeaut; S B Hanauer
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

9.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.

Authors:  R N Fedorak; A Gangl; C O Elson; P Rutgeerts; S Schreiber; G Wild; S B Hanauer; A Kilian; M Cohard; A LeBeaut; B Feagan
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

10.  Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Authors:  B E Sands; W J Tremaine; W J Sandborn; P J Rutgeerts; S B Hanauer; L Mayer; S R Targan; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325
View more
  13 in total

Review 1.  Risks and benefits of biologic therapy for inflammatory bowel diseases.

Authors:  Geert D'Haens
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

2.  Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula.

Authors:  C Hassan; A Zullo; E Ierardi; O Burattini; V De Francesco; S Morini
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

3.  No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases.

Authors:  Georgia Malamut; Candice Cabane; Laurent Dubuquoy; Mathilde Malapel; Benoit Dérijard; Jérôme Gay; Cyrus Tamboli; Jean-Frédéric Colombel; Pierre Desreumaux
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

Review 4.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  SD0006: a potent, selective and orally available inhibitor of p38 kinase.

Authors:  Barry L Burnette; Shaun Selness; Raj Devraj; Gail Jungbluth; Ravi Kurumbail; Loreen Stillwell; Gary Anderson; Stephen Mnich; Jeffrey Hirsch; Robert Compton; Pamela De Ciechi; Heidi Hope; Michael Hepperle; Robert H Keith; Win Naing; Huey Shieh; Joseph Portanova; Yan Zhang; Jian Zhang; Richard M Leimgruber; Joseph Monahan
Journal:  Pharmacology       Date:  2009-07-04       Impact factor: 2.547

Review 6.  Clinical pharmacokinetics and use of infliximab.

Authors:  Ulrich Klotz; Alexander Teml; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Infliximab therapy in children and adolescents with inflammatory bowel disease.

Authors:  Gabor Veres; Robert N Baldassano; Petar Mamula
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Safety of biologics in inflammatory bowel disease.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2006-06

9.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13

10.  The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice.

Authors:  Elisabeth Wende; Robert Laudeley; André Bleich; Eva Bleich; Rick A Wetsel; Silke Glage; Andreas Klos
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.